
Rucaparib is FDA approved in patients with a BRCA mutation and who have received 2 more prior lines of previous chemotherapy.

Rucaparib is FDA approved in patients with a BRCA mutation and who have received 2 more prior lines of previous chemotherapy.

Published: April 30th 2020 | Updated: